Tag: Edinburgh Cancer Centre

Improving cancer care

Funding for projects to benefit patients and clinical staff

A total of £1.5 million funding in 2024-25 is supporting 12 projects to continue providing direct and personalised support to patients with cancer.

The Single Point of Contact (SPoC) pilots provide patients with ongoing contact to support them, putting them at the heart of all decisions and actions involving them throughout their care journey.

The NHS Lothian SPoC uses a centralised digital hub delivering telephone communication and support to patients with a range of cancer types.

Around 40% of calls are diverted away from Clinical Nurse Specialist workload, which has led to improvements in the quality of their telephone contacts. Patient engagement work carried out by NHS Lothian and Healthcare Improvement Scotland has indicated high satisfaction with the service.

Confirming the funding, which is included in the 2024-25 Budget, as he met nurses at Edinburgh Cancer Centre with experience of the service, First Minister John Swinney said: “We are fully focused on improving cancer survival, and delivering excellent and accessible care is at the core of how we do that.

“The Single Point of Contact Service meets requirements identified by Boards to deliver improvements in communication and support for patients with navigating cancer care.

“By taking in the region of 2,000 calls per month and providing person-centred support to those patients throughout their care journey, the Edinburgh Single Point of Contact project provides consistent access for patients to have conversations about their care, freeing up capacity for specialist staff to focus on the most complex cases.”

Katie Gibson, Neuroendocrine Tumour Clinical Nurse Specialist at the Edinburgh Cancer Centre, said: “I’ve seen first-hand how the SPoC service has transformed our ability to care for cancer patients.

“The centralised system streamlines communication and allows us to spend more quality time with those who need it most.

“As a result, patients are aware of who to contact for the support and advice they require from diagnosis , treatment and beyond.”

Over £1.5 million will support 12 pilot projects across Scotland to deliver a single point of contact to people diagnosed with cancer.

Funding has been delivered in response to needs identified by individual Boards and proposals submitted by them, pilots vary by cancer type and location:

  • NHS Lothian has received £ 343,740 to support the telephone-based SPoC service at Edinburgh Western General, serving boards within the South East Scotland Cancer Network
  • NHS Borders has received £82,000 for 3 cancer care co-ordinators, providing support across a variety of cancer sites
  • NHS Dumfries and Galloway has received £71,000 for 2 cancer co-ordinator posts, providing a telephone-based support service across a range of tumour sites  
  • NHS Fife has received £107,354 to staff a Single Point of Contact Hub, dealing with all urgent suspected cancer referrals.  
  • NHS Forth Valley has received £67,556 for 2 healthcare support workers (HCSW) providing a single point of contact for 7 tumour groups
  • NHS Ayrshire and Arran, NHS Forth Valley, NHS Greater Glasgow and Clyde, and NHS Lanarkshire have received total funding of £202,668to develop a regional approach to digital remote follow up of prostate cancer patients in the West of Scotland
  • NHS Greater Glasgow and Clyde has received £67,566 for 2 support workers to augment specialist gynaecological nursing support  and £141,324 for 4 SPoC roles across GGC sites to smooth and facilitate the patient journey, for people diagnosed with lung cancer
  • NHS Grampian has received £84,500 for 3 posts to provide a joint service with Macmillan Navigators, providing support following an Urgent Suspicion of Cancer (USC) referral
  • NHS Highland has received £270,680 for 7 Cancer Support Workers providing tailored support throughout diagnostic pathway and onto treatment
  • NHS Tayside has received £33,288 to provide support for people diagnosed with advanced Upper Gastrointestinal or Hepatopancreatobiliary tumours and lung, renal and prostate cancers
  • NHS Western Isles has received £68,000 for 2 HCSWs, as part of the Macmillan Team, to support people with all types of cancer

Health Improvement Scotland is currently carrying out a scalability assessment of all 12 projects in order to identify best practice and how best to scale and expand these pilots.

Upgraded oncology services at Western General’s Edinburgh Cancer Centre now delivering care

Two units which provide vital care and treatment to some of the most unwell patients in Scotland have been transformed by NHS Lothian as part of a multi-million pound investment.

A new Cancer Assessment Unit (CAU) and an oncology ward for systemic anti-cancer treatment (SACT) are now open and delivering care to patients at the Edinburgh Cancer Centre (ECC).

The ECC, based in the Western General Hospital, supports an average of 7,000 inpatient admissions, 25,000 day-cases and 100,000 outpatient attendances each year from across the Lothians, Scottish Borders, Fife and Dumfries and Galloway.

The demand for treatment and services has significantly outgrown facilities and available space in recent times, but the new refurbishments have enabled significant modernisation to improve the care and overall experience for patients.

Chris Stirling, Site Director for the Western General Hospital, NHS Lothian, said: “This is a great step forward to upgrade our existing infrastructure.

“We know how important and reassuring a welcoming environment is at a worrying time, and we’re delighted that our current patients have access to better facilities.

“This is an important step in our ambition toward a new centre for the future of the southeast of Scotland to enable us to meet the rising demand of a growing population.”

The new CAU

The upgrades are part of a £24 million package of enabling works within oncology services, funded by the Scottish Government, which are due to be completed in 2024.

This is in advance of a longer-term plan for the full reprovision of the Edinburgh Cancer Centre which has been proposed by NHS Lothian in response to the population growth in the region and constraints of the existing ECC.

The refurbished SACT ward, which is where treatments like chemotherapy and immunotherapy are administered to patients, has seen an extensive programme of work – including new flooring, ceilings, paintwork, lighting, bed head services, fire safety upgrades and a new reception area.

There is now a dedicated space for patients to be assessed and prepped for their therapy, and comfortable chairs for patients to begin their treatment while awaiting a bed.

Four-bedded bays have been reconfigured into two-bedded bays, giving patients greater privacy. Where eight patients previously shared a bathroom, there is now an ensuite facility for every two beds.

The new CAU provides a fresh, purpose-built environment for patients to attend for assessment or diagnostic tests prior to potential admission to an inpatient hospital bed.

The CAU also has a dedicated family room with a double sofa bed and its own ensuite facility for relatives who may need to stay close to their loved one overnight.

Mrs McLean, 61 from Edinburgh, said: “Following a sudden and unexpected reaction to my treatment, I was taken to the new Cancer Assessment Unit. I was so grateful to be welcomed immediately by the medical team there.

“At such a worrying time for me, the nurses and doctor were not only reassuring, friendly and kind, but their professional clinical care was exceptional. Their thoughtfulness extended to my family sitting in the waiting area close to my treatment bay who were soon invited to join me.

“I really appreciated being in such a modern, comfortable facility and my experience of the CAU could not have been better or more positive. I can’t thank the medical staff enough for their excellent care of me in the new unit.”

Western General’s Cancer Navigation Hub is one year old

The Cancer Navigation Hub, based in Edinburgh Cancer Centre at the Western General Hospital, recently celebrated one year of the service launching.

The team helps patients and healthcare professionals to navigate cancer pathways, ensuring enquiries are directed to the appropriate care team in a timely and efficient way.

The team is made up of Cancer Pathway Coordinators and acts as a single point of contact for patients who’ve received a cancer diagnosis. Coordinators are also trained to assist healthcare professionals and helps to alleviate the pressure on clinical teams.

Katie Seville, Assistant Service Manager in Cancer Performance, said: “In just one year we’ve seen the hub make such a difference to the ease with which patients and staff can access the information and support they need.

“The team is in high demand and we’re looking to further expand and grow the service into new areas, providing more personalised and holistic support for patients throughout their diagnosis and treatment.”

The Cancer Navigation Hub initially served five tumour groups – lung, melanoma, head and neck, gynaecology, and urology. In April 2023, the hub expanded to cover the neuroendocrine tumour group followed by breast in August 2023.

During the first five months of the service (October 2022 to February 2023) the team handled on average over 1,100 calls per month, 38% of which were administrative queries or issues that could be resolved by the Cancer Pathway Coordinators.

In the month after incorporating the breast service, the team handled just over 1,900 calls across all tumour groups, with 44% of all calls being dealt with by the coordinators.

Since January 2023, the Cancer Navigation Hub has also been proactively calling newly diagnosed patients to introduce the hub and direct patients to support services.

In June 2023, during the launch of the new Cancer Strategy, the team was among those to meet Michael Matheson, Cabinet Secretary for NHS Recovery, Health and Social Care.

Congratulations to the team for a brilliant first year.

Wonderful Western General workers celebrate success

Local healthcare workers at the Western General Hospital (WGH) in Edinburgh have been honoured for their exceptional work at a prestigious ceremony.

The annual NHS Lothian Celebrating Success Awards 2023 are nominated by staff working across the healthcare system.

Among the winners are the Same Day Emergency Care Team (SDEC) who scooped the coveted Team of the Year Award for the work they do helping patients get the right care in the right place.

The team are helping to reduce waiting times and pressure on the front doors by assessing, diagnosing, treating and discharging patients with specific conditions without admission to a ward.

Michael Shek, Lead Advance Nurse Practitioner for SDEC said: “We’ve put in so much work to make SDEC a successful service and we continue to expand.

“It’s not just the SDEC team but everyone wider. None of this would have been possible without everyone in NHS Lothian’s help. This award is recognition of that hard work and it will help drive the team forward to provide even better care.”

Kirsten Smith, a Senior Charge Nurse for Acute Medicine who won the cherished Lynn Jackson Nurse of the Year Award in memory of the former Chief Nurse for Edinburgh Cancer Centre.

Kirsten was recognised for leading her team on a huge change journey from specialising in Medicine for the Elderly to providing care to acute medical admissions and her commitment to working with student nurses.

Finally, Zakariya Vansoh (18), won the Voluntary Service Award for the hundreds of hours he’s clocked up connecting with patients, helping to entertain, comfort and reassure them, or just lend a friendly ear.

Celebrating with his Gran at the ceremony Zak said: “I’m speechless, I had my granny record it, but I didn’t think I was going to win so speechless!

“The fact that I was even nominated for the award is already more than I could ever have imagined.  Events like this one today are so important to let people feel really appreciated. It’s simple but so valuable.”

Professor John Connaghan CBE, Chair of NHS Lothian Board said: “It’s been a very special year as we celebrated the 75th anniversary of the NHS. We’re incredibly proud of our staff achievements over the decades and their commitment to caring for others.

“These awards ensure we recognise those who’re not just upholding the NHS values but also helping us evolve and transform for the future.”

The awards were presented on Thursday 7 September at a special Ceremony at the Kimpton Charlotte Square Hotel, sponsored by NHS Lothian Charity.

Calum Campbell, Chief Executive, NHS Lothian, added: “Many of our staff feel like they’re just doing their job and don’t want recognition, which is why these awards are so important.

“I want to thank all our finalists for their hard work, resilience and professionalism and extend a warm congratulations to them all for their achievements.” 

The NHS Lothian awards are also supported by Ernst & Young, Intersystems, RMF Health (a partnership between Robertson and FES Group), Royal College of Nursing Scotland, Unison and NHS Staff Benefits.

For the full list of all of NHS Lothian’s award winners please visit:

news.nhslothian.scot/celebrating-success-finalists.

Edinburgh Cancer Centre investigates COVID-19 immunity in cancer patients

Researchers from NHS Lothian and the University of Edinburgh have conducted a clinical study to investigate the extent to which cancer and cancer treatment affects COVID-19 immunity.

Blood samples were taken regularly from over 760 consenting patients, most from Southeast Scotland, who were receiving routine treatments for cancer.

The samples were then tested for signs of an immune response to COVID-19 using an antibody test.

The study is the largest of its kind in the world with the first patients being recruited in May 2020, just months after the United Kingdom experienced its first lockdown.

Dr Peter Hall, Consultant Medical Oncologist at Edinburgh Cancer Centre, said: “Treatments such as chemotherapy can affect the immune system, so it was really important for us to understand the effects of COVID-19 on people undergoing anti-cancer treatment.

“We now have a better understanding of how the virus affects these patients in the short and long-term, and to what extent the vaccine had an impact on their antibodies.

“It’s very reassuring to see that most cancer patients can go ahead with their treatments without fear of excessive risk from COVID-19, and that vaccination offers an effective means of protection.”

The study found that COVID-19 infection rates in patients with cancer largely mirrored those of their local population and that treatment type did not impact the rate of their antibody response.

It also concluded that vaccination was effective in protecting people with cancer from COVID-19.

Dr Hall continued: “More research is needed, but this was an important step in understanding how people receiving anti-cancer treatment are impacted by the virus.

“It’s also another example of NHS Lothian and the University of Edinburgh working collaboratively to understand how best to care for some of the most vulnerable patients.”

You can read the Scottish COVID Cancer Immunity Prevalence Study in full in The Oncologist.

NHS Lothian helps pioneer new treatment for kidney cancer patients

A kidney cancer drug has been accepted for use within NHS Scotland and across the UK thanks to an international study, with NHS Lothian and Edinburgh University leading the UK part of the trial.

The treatment, pembrolizumab, is an antibody delivered intravenously as an immunotherapy to reduce the chances of a relapse after kidney cancer surgery.

Thanks to the research, the Scottish Medicines Consortium (SMC) has advised that the drug will now be made available to treat eligible adults with renal cell carcinoma (RCC).

In Scotland, about 1000 patients are diagnosed with RCC each year, and the incidence of the disease has been increasing over time.

Surgery carries the hope of cure if disease is caught early, but about a quarter to half of patients who undergo a nephrectomy (whole or partial kidney removal) have disease recurrence at different sites within three to five years of this.

RCC is generally resistant to chemotherapy and radiation therapy so, until now, there have been no additional treatments that reduce this risk of relapse.

The study showed that, for patients with a raised risk of relapse, pembrolizumab reduced the risk of kidney cancer coming back by a about a third and there are early indications that this is leading to patients living longer.

This has led to the SMC recommending the drug for NHS use and the first non-trial patients are now receiving this new treatment in Edinburgh.

Dr Stefan Symeonides, Senior Lecturer at the University of Edinburgh and Oncology Consultant at the Edinburgh Cancer Centre, said: “Research continues to explore which people might benefit most from this treatment, as pembrolizumab is not always effective or suitable for every patient.

“However, this represents a significant breakthrough in the treatment of kidney cancer as confirmed by UK approvals from the SMC in Scotland and NICE in England and Wales, as well as its incorporation in treatment guidelines from the European Society for Medical Oncology (ESMO).

“Approval of pembrolizumab is welcome news to many RCC patients, who otherwise had no treatment options available to them to prevent or reduce the risk of relapse of the cancer following nephrectomy.”

Visit the University of Edinburgh‘s website to read more.

Skin Cancer Awareness Month: NHS Lothian patients share experiences

Two patients have spoken out on Skin Cancer Awareness Month about the difference NHS Lothian’s treatment has made to their lives. 

Alan Vannan, 62 from Peebles, was diagnosed with squamous cell carcinoma (SCC), the second most common skin cancer, and has been administered with immunotherapy for two years.

Prior to this, patients like Alan with advanced SCC who’ve exhausted other treatment, such as surgery and radiotherapy, wouldn’t have had other options.

Alan said: “It started with a lump on my neck and cheek, so I went to the GP. 

“When I saw the doctor at St John’s, he took one look and diagnosed it as skin cancer and said they’d need to operate on it quickly. A Macmillian nurse, who’s been brilliant, called me on the way home.

“Processing what people are telling you after a cancer diagnosis can be the most difficult part. 

“Next was the surgery followed by radiotherapy, which wasn’t easy. Beforehand, I always thought of skin cancer as something minor and easily treated.”

Unfortunately, after his treatment, Alan received the news that the cancer hadn’t gone away.

Alan continued: “That was a difficult time. They couldn’t operate further. It came as a bit of a shock. Mentally, it was hard to process. They told me I had months left and that’s when I went to Dr Mackenzie. 

“I was given immunotherapy and it’s the best thing that’s happened to me. I’ve gone from being told I had months to it being two years later. 

“As soon as I started taking the drug the wound healed up. For me, it’s been absolutely fantastic. Every time I’ve got a scan I expected it to get worse, but it never has.

“I can’t praise the staff highly enough. The nurses, surgeons, radiologists and oncologists at the Western General and St John’s, and the Macmillian nurses, have all been amazing.”

Dr Joanna Mackenzie, Consultant Clinical Oncologist at Edinburgh Cancer Centre (above), said: “We’re always looking for ways to improve how we support our patients, and this has been a huge step forward in our management of difficult skin cancers. 

“To see it make such a difference to people like Alan who, just a few years ago, we wouldn’t have had the tools to help is really fulfilling for us as a team. 

“We’re also looking to conduct research to see if immunotherapy can be used at an earlier stage to help a wider number of patients with SCC.”

NHS Lothian last year also invested in a new superficial x-ray machine which treats basal cell carcinoma (BCC), the most common type of skin cancer. 

The machine is used for patients where surgery is not the preferred option, which can be due to other health conditions or the location of the cancer. 

BCC is rarely life-threatening but is typically seen on the face and attacks surrounding healthy tissue, sometimes leading to deformity. 

Lynda Gordon, 74, from Joppa, said: “About two years ago, I woke up with a hole at the end of my nose, so I contacted the GP.

“I was referred to the hospital at Lauriston and had an appointment to meet with a plastic surgeon, an oncologist and a dermatologist at the Joint Cutaneous Oncology Clinic. 

“It was diagnosed as a BCC and I chose to receive radiotherapy.

“An operation would have required taking skin from elsewhere and because I’ve had that before, with an SCC in 2017, I couldn’t go through that again.

“I went for the procedure at the cancer centre in February with this new machine. 

“I went every weekday for one week. Staff are lovely and make sure to explain everything. It only takes about two minutes each time. 

“The healing process was a bit unpleasant but three to four weeks later it settled, and my nose is looking absolutely fine. I’m really pleased with the results. 

“The care provided by staff is just brilliant.”

This Skin Cancer Awareness Month, NHS Lothian is also urging everyone to take simple precautions when enjoying the sun.

Dr Mackenzie continued: “It’s easy for us to think that, because we see many months of cold weather, the summer months can’t cause too much damage. 

“But whether at home or abroad, we all need to make the effort to protect our skin. 

“Simple ways to do so are avoiding the sun at peak times and wearing high-factor sunscreen as well as hats, sunglasses and clothing which covers sensitive areas more prone to sun damage.

“Please contact your GP if you’re concerned about any unusual changes to your skin.”

Local patients can access new cancer treatment

New prostate cancer treatment available at Edinburgh Cancer Centre is first in Scotland

Men in the South East of Scotland may now be able to access a new treatment for prostate cancer, which is available at the Edinburgh Cancer Centre, Western General Hospital.

The Edinburgh Cancer Centre (ECC) is the first in Scotland to offer High–dose-rate brachytherapy (HDR-BT) for treatment of prostate cancer.

It was successfully introduced by NHS Lothian earlier this year and is now being made available to suitable patients across the South East of Scotland.

Prostate cancer is the most common cancer among Scottish males affecting 1 in 10 men. With more than 3,000 men diagnosed every year this figure is only expected to increase.

But, with early detection and improved treatments, survival rates are also increasing. Radiotherapy is commonly used to cure prostate cancers and increasing the radiation dose in treatments has shown to improve long-term cancer control.

The HDR-BT service at the ECC offers an additional treatment approach to deal with aggressive but localised prostate cancer. It allows a higher dose of radiation to be targeted directly into the prostate gland in a safe and controlled way. This minimises radiation exposure to surrounding normal tissue and thereby reduces potential side effects.

The new treatment is being offered alongside existing radiotherapy treatments at the Edinburgh Cancer Centre, expanding the range of treatment options on offer. 

Dr Aravindhan Sundaramurthy, Consultant Clinical Oncologist at the Edinburgh Cancer Centre explains: “We have been successfully delivering low-dose-rate brachytherapy (LDR-BT) for prostate cancer with over 1000 men throughout Scotland benefitting from the service. However, men with more advanced or aggressive disease would not be eligible for LDR-BT on its own.”

“The start of the new HDR-BT service opens a very important therapeutic option for men with high-risk prostate cancer features. It brings together the skills and expertise of staff across our radiotherapy, oncology and anaesthetic teams to deliver another treatment option.”

Roderick Sanderson (62) from Dumfries & Galloway was the first patient to receive this new treatment at the Edinburgh Cancer Centre. 

He said: “I would strongly encourage anyone who is offered this treatment to go for it. It was a very smooth process and the care I received from the NHS was absolutely first class. I was looked after every step of the way and I knew that I was in the best possible hands for my treatment.”

This HDR-BT service is a collaborative effort involving radiotherapy nursing, prostate clinical oncologists, anaesthetics, therapeutic radiographers and oncology physicists.  It is currently being offered at the Edinburgh Cancer Centre for suitable patients within the South-east Scotland Cancer Network with an aim to expand the service to other patients across Scotland.

Anyone looking for more information about prostate cancer including details of common symptoms and testing can visit NHS Inform: www.nhsinform.scot/illnesses-and-conditions/cancer/cancer-types-in-adults/prostate-cancer